China's Anpac Lands Series A Investment for Cancer Screening Test

Anpac Bio-Medical Science Co. of Shanghai announced that Shanghai Zhangjiang Science &Technology Investment Corporation made a Series A investment in Anpac equivalent to "several million dollars." Using its Cancer Differentiation Analysis (CDA) technology, Anpac has developed a series of diagnostics with high rates of sensitivity and specificity for early cancer screening. Anpac said it would use the funds to add a US headquarters and clinical trials to its China operations. More details.... Share this with colleagues: // //